Aerovate Therapeutics (AVTE) News Today $2.53 -0.03 (-1.17%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period GSA Capital Partners LLP Purchases 287,163 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)GSA Capital Partners LLP raised its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 226.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 413,795 shares of theNovember 17 at 3:52 AM | marketbeat.comWedbush Predicts Higher Earnings for Aerovate TherapeuticsNovember 17 at 2:18 AM | americanbankingnews.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 17.3%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 549,800 shares, a decrease of 17.3% from the October 15th total of 665,000 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average daily volume of 750,300 shares, the short-interest ratio is currently 0.7 days.November 15 at 8:43 PM | marketbeat.comWedbush Forecasts Higher Earnings for Aerovate TherapeuticsAerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Analysts at Wedbush boosted their FY2024 EPS estimates for Aerovate Therapeutics in a research note issued to investors on Wednesday, November 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($2.85) per share forNovember 15 at 7:35 AM | marketbeat.com$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of BMTX, AVTE, ALTR and PFIENovember 13, 2024 | stockhouse.comAerovate Therapeutics Reports Q3 Loss Amid Strategic ShiftNovember 13, 2024 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALTR, MPB, AVTE on Behalf of ShareholdersNovember 8, 2024 | stockhouse.comINVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTENovember 5, 2024 | globenewswire.comINVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTENovember 3, 2024 | prnewswire.comTizona’s TTX-080 colorectal cancer trial expands with new armsNovember 3, 2024 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of ShareholdersNovember 1, 2024 | prnewswire.comAerovate Therapeutics, Jade Biosciences enter merger agreementOctober 31, 2024 | markets.businessinsider.comAerovate Therapeutics and Jade Biosciences Announce Strategic MergerOctober 31, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Aerovate Therapeutics, Inc. (AVTE)October 31, 2024 | markets.businessinsider.comAerovate Therapeutics and Jade Biosciences Announce Merger AgreementOctober 31, 2024 | markets.businessinsider.comAerovate climbs on all-stock merger deal with JadeOctober 31, 2024 | msn.comShareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersOctober 31, 2024 | businesswire.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 21.4%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 665,000 shares, a decline of 21.4% from the September 30th total of 846,500 shares. Based on an average trading volume of 240,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.4% of the company's stock are sold short.October 28, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 20.9% in SeptemberAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 846,500 shares, a drop of 20.9% from the September 15th total of 1,070,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average daily volume of 284,900 shares, the short-interest ratio is currently 3.0 days.October 13, 2024 | marketbeat.comDeerfield Management Company L.P. Series C Takes Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Deerfield Management Company L.P. Series C acquired a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,411,608 shares of thSeptember 26, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Receives Average Recommendation of "Hold" from AnalystsShares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) have earned a consensus recommendation of "Hold" from the six brokerages that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating. The average twelve-month price objeSeptember 1, 2024 | marketbeat.comShort Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Decreases By 6.4%Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 842,600 shares, a decrease of 6.4% from the June 30th total of 900,400 shares. Currently, 4.4% of the shares of the stock are short sold. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 0.8 days.July 30, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Given Consensus Recommendation of "Hold" by AnalystsShares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) have received an average rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating. The average 1 year price target among brJuly 13, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Up 4.2%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 4.2%July 11, 2024 | marketbeat.comAerovate Therapeutics to Explore Strategic AlternativesJuly 8, 2024 | globenewswire.comInvestigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCJune 21, 2024 | globenewswire.comAerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law FirmJune 20, 2024 | globenewswire.comAerovate Therapeutics (NASDAQ:AVTE) Rating Reiterated by Jefferies Financial GroupJefferies Financial Group reiterated a "hold" rating and issued a $2.00 price target (down from $65.00) on shares of Aerovate Therapeutics in a research report on Monday.June 17, 2024 | marketbeat.comSHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & LevitonJune 17, 2024 | globenewswire.comAerovate Therapeutics (NASDAQ:AVTE) Lowered to Neutral at BTIG ResearchBTIG Research downgraded Aerovate Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday.June 17, 2024 | marketbeat.comAerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionJune 17, 2024 | globenewswire.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 15,000 Shares of StockJune 15, 2024 | insidertrades.comOctagon Capital Advisors LP Lowers Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Octagon Capital Advisors LP lowered its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 18.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 403,685 shares of the company's stock after selling 93,685 sharesJune 15, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Up 3.6%Aerovate Therapeutics (NASDAQ:AVTE) Trading Up 3.6%June 13, 2024 | marketbeat.comGreat Point Partners LLC Decreases Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Great Point Partners LLC lowered its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 4.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,037,690 shares of the comJune 13, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Down 2% Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 2%June 12, 2024 | marketbeat.comAerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH MarketJune 11, 2024 | seekingalpha.comVestal Point Capital LP Makes New $9.05 Million Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)Vestal Point Capital LP acquired a new position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 400,000 shares of the company's stock, valued at approximatelJune 9, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Down 6.8%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Down 6.8%June 6, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Stock Rating Reaffirmed by WedbushWedbush restated an "outperform" rating and issued a $41.00 target price on shares of Aerovate Therapeutics in a report on Thursday.June 6, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Trading Up 10.9%Aerovate Therapeutics (NASDAQ:AVTE) Shares Up 10.9%June 5, 2024 | marketbeat.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 16.5% in MayAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 2,190,000 shares, a growth of 16.5% from the April 30th total of 1,880,000 shares. Approximately 12.0% of the company's stock are short sold. Based on an average trading volume of 167,500 shares, the days-to-cover ratio is currently 13.1 days.May 31, 2024 | marketbeat.comAerovate Therapeutics (NASDAQ:AVTE) Shares Up 5.6%Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 5.6%May 30, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)May 22, 2024 | markets.businessinsider.comWedbush Reaffirms Outperform Rating for Aerovate Therapeutics (NASDAQ:AVTE)Wedbush restated an "outperform" rating and set a $41.00 target price on shares of Aerovate Therapeutics in a report on Wednesday.May 22, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)May 22, 2024 | markets.businessinsider.comAerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceMay 21, 2024 | globenewswire.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells 4,000 Shares of StockMay 18, 2024 | insidertrades.comInsider Selling: Aerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells 10,000 Shares of StockMay 18, 2024 | insidertrades.comAerovate Therapeutics, Inc. (NASDAQ:AVTE) CEO Sells $215,800.00 in StockAerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) CEO Timothy P. Noyes sold 10,000 shares of the company's stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $21.58, for a total value of $215,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.May 17, 2024 | marketbeat.com Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov AVTE Media Mentions By Week AVTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVTE News Sentiment▼1.190.56▲Average Medical News Sentiment AVTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVTE Articles This Week▼122▲AVTE Articles Average Week Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CytomX Therapeutics News Today Immunic News Today Gossamer Bio News Today Zura Bio News Today AC Immune News Today biote News Today Lyell Immunopharma News Today Biomea Fusion News Today UroGen Pharma News Today Immutep News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVTE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts